Bladder Cancer

FDA approves additional recommended dosage for anti-PD-1 therapy

May 13, 2020

The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.

53% of CIS patients achieve complete response with nadofaragene

May 13, 2020

Nadofaragene firadenovec, a novel intravesical gene-mediated therapy, achieved complete response in 53.4% of patients with bacillus Calmette Guérin-unresponsive carcinoma in situ, according to findings from a phase III trial. First author Stephen A. Boorjian, MD, professor of urology at Mayo Clinic, Rochester, MN, discusses the study results and their implications.

How new agents may address NMIBC treatment challenges

April 24, 2020

Systemic and intravesical therapies are changing the landscape of BCG-unresponsive disease, according to Matthew Galsky, MD.

Study evaluates targeted FGFR3 therapy for UTUC vs. UTB

April 22, 2020

New results from a study investigating infigratinib in patients having metastatic urothelial carcinoma with activating FGFR3 mutations and/or fusions indicate that the investigational selective fibroblast growth factor receptor 1 to 3 (FGFR1-3) tyrosine kinase inhibitor may have greater activity for treating upper tract urothelial carcinoma than for urothelial carcinoma of the bladder.

Neoadjuvant durvalumab feasible in muscle-invasive bladder Ca

April 09, 2020

Durvalumab (IMFINZI) appears to be feasible as neoadjuvant therapy with preliminary evidence of antitumor activity in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Interleukin-15 agonist complex earns breakthrough therapy designation

March 25, 2020

ImmunityBio announced that the FDA has granted Breakthrough Therapy designation for its interleukin-15 agonist complex, N-803, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of patients with BCG-unresponsive nonmuscle-invasive bladder carcinoma in situ.

Enfortumab granted breakthrough therapy designation for metastatic urothelial Ca

March 18, 2020

The FDA has granted Breakthrough Therapy designation for enfortumab vedotin-ejfv (PADCEV) in combination with the anti-PD-1 therapy pembrolizumab (KEYTRUDA) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.

Bladder-sparing treatments linked with high rates of progression in NMIBC subset

March 04, 2020

High-grade nonmuscle-invasive bladder cancer is characterized by high rates of disease progression following introduction of bladder-preservation therapy after treatment with Bacillus Calmette-Guérin.

Checkpoint inhibitor Tx response similar between pure, variant UC histologies

March 04, 2020

“Histologic subtype shouldn’t exclude patients from getting checkpoint inhibitor therapy,” says Natalie J. Miller, MD, PhD.

Sequential gemcitabine/docetaxel promising for recurrent NMIBC

February 28, 2020

"In this era of BCG shortage, we may be forced to develop new standards and alternative strategies for bladder preservation," writes Badar M. Mian, MD.